Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integrated BiopharmaINBP 36 OCF Yield % is 60.89 as of Jul. 31, 2026, which is 366% above its 10-year median of 13.07. GuruFocus rates INBP with a GF Score™ of 36/100 and a GF Value™ of $0.26 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,988 Consumer Packaged Goods companies, Integrated Biopharma ranks better than 97.13% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Integrated Biopharma OCF Yield % Related Terms
Integrated Biopharma OCF Yield % Historical Data
* Premium members only.
The historical data trend for Integrated Biopharma's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Integrated Biopharma's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrated Biopharma OCF Yield % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Integrated Biopharma's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Integrated Biopharma's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integrated Biopharma (INBP) has a OCF Yield % of 60.89 as of Jul. 31, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Integrated Biopharma and its competitors. This is 366% above median its historical median of 13.07. According to the industry distribution chart, Integrated Biopharma ranks #57 out of 1988 companies in the Consumer Packaged Goods industry, placing it in the top 2.9%.
Is Integrated Biopharma's OCF Yield % too high?
Integrated Biopharma's current OCF Yield % of 60.89 is 366% above median its 10-year median of 13.07. The Consumer Packaged Goods industry median OCF Yield % is 6.49. Integrated Biopharma's value of 60.89 is 838.9% above this industry median. Based on the distribution chart, Integrated Biopharma ranks #57 out of 1988 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Integrated Biopharma has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Integrated Biopharma's OCF Yield % compare to HCWC and PAVS?
According to the Consumer Packaged Goods industry distribution chart, Integrated Biopharma ranks #57 out of 1988 companies for OCF Yield %. This places Integrated Biopharma in the top 3% of its industry — outperforming the majority of peers. The industry median OCF Yield % is 6.49. Integrated Biopharma's value of 60.89 is 838.9% above this benchmark. While the company's 10-year median is 13.07 vs. the industry median of 6.49, Integrated Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Consumer Packaged Goods company?
The median OCF Yield % among Consumer Packaged Goods companies is 6.49, based on 1,988 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integrated Biopharma's current OCF Yield % of 60.89 is 838.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Integrated Biopharma and its competitors. For the Consumer Packaged Goods industry, the median OCF Yield % is 6.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integrated Biopharma's current OCF Yield % is 60.89, which is 366% above median its own 10-year median of 13.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Integrated Biopharma (INBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.26, compared to a current price of $0.16 — trading 38.5% below its estimated fair value. The current OCF Yield % is 60.89, which is 366% above median its 10-year median of 13.07 and 838.9% above the Consumer Packaged Goods industry median of 6.49. Integrated Biopharma's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Integrated Biopharma (INBP), the current OCF Yield % is 60.89 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrated Biopharma (INBP) Overvalued in 2026?
Based on GuruFocus' analysis, Integrated Biopharma stock appears to be undervalued.
The current stock price of $0.16 is trading 38.5% below its estimated GF Value™ of $0.26.
GuruFocus considers Integrated Biopharma to be Possible Value Trap.
Key valuation signals for INBP:
OCF Yield %: 60.89 (366% above median its 10-year median of 13.07)
GF Value™: $0.26 vs. price of $0.16 (38.5% below fair value)
Industry Position: 838.9% above the Consumer Packaged Goods median (#57 of 1988)
No single metric tells the full story. See the INBP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments: Contract Manufacturing and Other Nutraceutical Businesses. Key revenue is generated from the Contract Manufacturing segment, which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers.
36GF Score
Get the complete analysis for INBP
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INBP has been successfully added to your 
